Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 28;13(5):1003. doi: 10.3390/cancers13051003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The combination of MEDS433 with classical antileukemic agents results in near-additive effects. (A) Apoptosis induced by MEDS433, Ara-C and their combination on MV4-11 (left panel, n = 4) and THP1 (right panel, n = 3) cells. (B) Apoptotic rate (left panel) and cell viability (right panel) of THP1 cells treated with MEDS433, idarubicin or both (n = 3). (C) Apoptotic rate (left panel, n = 3) and cell viability (right panel, n = 3) of THP1 cells treated with decitabine, MEDS433 or both, with or without physiological levels of uridine (5 µM). If not otherwise specified, MEDS433 was utilized at 0.1 µM. Apoptosis and cell counts were evaluated after 3 days of treatment. DMSO: dimethyl sulfoxide. M: MEDS433. A: Ara-C. Ida: idarubicin. Dec: decitabine. Statistical significance: Anova/Tukey, * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.